Physician profile
Bijender Kumar
NPI 1033375084
$1,568.79
in general payments reported to CMS, 2019-2025
30 companies · $42.23 in 2025
The $42.23 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $90.41 · 2021: $167 · 2022: $225 · 2023: $222 · 2024: $34.99 · 2025: $42.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $298.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $302.08 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $194.29 | 2019-2023 | Lokelma |
| Aquestive Therapeutics, INC. | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $93.22 | 2021-2023 | |
| Pfizer INC. | $78.66 | 2019-2023 | |
| Glaxosmithkline, LLC. | $74.77 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Mylan Specialty L.P. | $63.83 | 2019-2023 | Yupelri |
| Exact Sciences Corporation | $58.46 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $46.34 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $42.45 | 2019 | |
| Abbvie INC. | $40.02 | 2019-2024 | |
| Dexcom, INC. | $38.91 | 2022-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $34.75 | 2022 | |
| Merck Sharp & Dohme LLC | $34.45 | 2022 | |
| Abbott Laboratories | $33.80 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $33.42 | 2019-2023 | Spravato |
| Amarin Pharma, INC. | $31.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $30.36 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.99 | 2021 | |
| Horizon Therapeutics Plc | $28.35 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $25.45 | 2021 | |
| Phadia US INC. | $20.96 | 2025 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.97 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.76 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.50 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.75 | 2021 | |
| Sanofi Pasteur INC. | $13.22 | 2019 | |
| Circassia INC. | $12.75 | 2019 | |
| Allergan, INC. | $12.47 | 2019 | |
| Vertiflex, INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bijender Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.